| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.26 | 4e-17 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.2 | 3e-09 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.24 | 8e-09 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-08 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.18 | 7e-08 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.21 | 2e-07 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.15 | 7e-06 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.19 | 1e-05 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.14 | 9e-05 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0002 |